{"id":4950,"date":"2017-05-29T12:00:53","date_gmt":"2017-05-29T12:00:53","guid":{"rendered":"https:\/\/www.ftcguardian.com\/articles\/?p=4950"},"modified":"2017-05-29T12:00:53","modified_gmt":"2017-05-29T12:00:53","slug":"1-6-million-settlement-by-opioid-maker-in-deceptive-advertising-case","status":"publish","type":"post","link":"https:\/\/www.ftcguardian.com\/articles\/1-6-million-settlement-by-opioid-maker-in-deceptive-advertising-case\/","title":{"rendered":"$1.6 Million Settlement by Opioid Maker in Deceptive-Advertising Case"},"content":{"rendered":"<h1>Opioid maker agrees to $1.6 million settlement in deceptive-advertising case, officials say<\/h1>\n<p>By <a href=\"https:\/\/www.ftcguardian.com\/articles\/rirr\">Sean Emery<\/a><\/p>\n<p>A pharmaceutical company has agreed to a $1.6 million settlement with Southern and Northern California prosecutors over allegations of deceptive advertising of opioid painkillers, Santa Clara officials announced this week.<\/p>\n<p>The agreement between Teva Pharmaceuticals, the Santa Clara County Counsel\u2019s Office and the Orange County District Attorney\u2019s Office would head off a civil trial. \u00a0Teva and four other companies were accused of engaging in deceptive marketing that helped spawn an addiction epidemic.<\/p>\n<p><a class=\"popup_7TLM_Cheat_Sheet\" data-toggle=\"modal\" data-target=\"#popup_7TLM_Cheat_Sheet_modal\" href=\"#\"><img decoding=\"async\" class=\"aligncenter\" src=\"\/images\/button_banner-7TLM_Cheat_Sheet.png\" alt=\"\" \/><\/a><\/p>\n<p>\u201cOur residents have borne the costs of the deceptive marketing scheme conducted by opioid drug companies,\u201d said Danny Chou, an assistant county counsel for Santa Clara County, in a statement. \u201cThese costs include not only the horrors of addiction for entire families and communities but also increased crime.\u201d<\/p>\n<p>Attorneys with the Orange County District Attorney\u2019s Office and the Santa Clara County Counsel\u2019s Office allege that a joint\u00a0investigation turned up a \u201cdecades-long scheme by the largest manufacturers of prescription opioid painkillers\u201d to downplay the risks of their drugs while exaggerating the benefits.<\/p>\n<p><a href=\"http:\/\/go.ftcguardian.com\/bw4uoy\"><img decoding=\"async\" src=\"https:\/\/s3.amazonaws.com\/ftcguardian\/images\/728x90-Un-vjy-FTC-GUARDIAN-banner-2.gif\" \/><\/a><\/p>\n<p>The lawsuit alleges that marketing campaigns by Teva \u2013\u00a0as well as Purdue Pharma, Endo Health Solutions, Janssen Pharmaceuticals and Actavis \u2013\u00a0helped transform prescription opioids from a niche market geared toward short-term use by cancer patients into a multi-billion-dollar industry in which the highly addictive drugs were\u00a0used to treat patients with chronic pain.<\/p>\n<p>Read full article and learn more about <a href=\"https:\/\/www.ftcguardian.com\/articles\/rirr\">Deceptive Advertising here<\/a>.<\/p>\n<h2>Here\u2019s How To Make Sure You,\u00a0Your Business & Website Is FTC Compliant<\/h2>\n<p>By now it should be clear how important it is for you to be FTC compliant. But how can you do that without spending $7,500-$8,000 or more on Internet Attorneys?<\/p>\n<p>Smart business owners around the world are doing it with the help ofFTC Guardian.<\/p>\n<p>FTC Guardian is a service that is 100% focused on helping to keep you get and stay FTC compliant and fully protected. <a href=\"https:\/\/go.ftcguardian.com\/bw4uoy\" target=\"_blank\" rel=\"noopener noreferrer\">And right now, we are offering a free training to give you the knowledge, information, and guidance that you need to stay out of trouble with the Federal Trade Commission.<\/a><\/p>\n<p>The training is titled: <a href=\"https:\/\/go.ftcguardian.com\/bw4uoy\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>3 Tragic (Legal) Privacy Policy List Building Mistakes That Can Get You In Hot Water With The FTC Today \u2013 Resulting In Your Business Being Shut Down\u2026 And How To Solve It!<\/strong><\/a><\/p>\n<p>Here are some of the things you\u2019ll discover on the training:<\/p>\n<ul>\n<li>Real-Life Examples of People Who Didn\u2019t Think They Were At Risk, But Who Got Nailed By The FTC, And Why It Could Happen To You, Too<\/li>\n<\/ul>\n<ul>\n<li>The 3 Enormous Powers The FTC Has That Can Change Your Life \u2013 And Your Family\u2019s Life \u2013 Forever!<\/li>\n<\/ul>\n<ul>\n<li>How to Avoid FTC Claims When Collecting Leads With Optin Forms<\/li>\n<\/ul>\n<ul>\n<li>3 Privacy Policy Mistakes Every Digital Marketer Is Making, And Why You\u2019re In The FTC\u00a0Crosshairs.<\/li>\n<\/ul>\n<ul>\n<li>And Much More\u2026<\/li>\n<\/ul>\n<p><b>Remember: legal protection is a massively important part of your business, and it\u2019s one you cannot afford to ignore any longer.<\/b><\/p>\n<p><a href=\"https:\/\/go.ftcguardian.com\/bw4uoy\" target=\"_blank\" rel=\"noopener noreferrer\">Go here to register for our next FREE training and make your business is FTC compliant today!<\/a><\/p>\n<p><b>Disclaimer: \u00a0This article is provided for informational purposes only. It\u2019s not legal advice, and no attorney-client relationship is created. Neither the author nor FTC Guardian, Inc. is endorsed by the Federal Trade Commission.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Opioid maker agrees to $1.6 million settlement in deceptive-advertising case, officials say By Sean Emery A pharmaceutical company has agreed to a $1.6 million settlement with Southern and Northern California prosecutors over allegations of deceptive advertising of opioid painkillers, Santa &hellip;  <\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_analytify_skip_tracking":false,"footnotes":""},"categories":[19,12,29],"tags":[11,21,32,30],"class_list":["post-4950","post","type-post","status-publish","format-standard","hentry","category-deceptive-advertising","category-ftc-compliance","category-truth-in-advertising","tag-ad-claims","tag-deceptive-advertising","tag-marketing","tag-truth-in-advertising"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/posts\/4950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/comments?post=4950"}],"version-history":[{"count":3,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/posts\/4950\/revisions"}],"predecessor-version":[{"id":4979,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/posts\/4950\/revisions\/4979"}],"wp:attachment":[{"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/media?parent=4950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/categories?post=4950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ftcguardian.com\/articles\/wp-json\/wp\/v2\/tags?post=4950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}